Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | +7.73% | +11.57% | -14.55% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.68 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.55% | 441M | D+ | ||
+43.76% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.55% | 351B | C+ | ||
+19.54% | 328B | B- | ||
+8.02% | 292B | C+ | ||
+11.92% | 216B | B- | ||
-2.62% | 214B | A+ | ||
+1.62% | 167B | C+ | ||
+7.21% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ESPR Stock
- Ratings Esperion Therapeutics, Inc.